Login to Your Account


EPO heave-ho? Acceleron Pharma raises $120M for rival anemia drug

By Randy Osborne
Staff Writer

Thursday, January 23, 2014
Squaring off against anemia leader Amgen Inc., with help from high-powered partner Celgene Corp., Acceleron Pharma Inc. expects to raise $120 million through the sale of 2.4 million shares at $50 each.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription